Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 2/20 | 0.62 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | GSK3B | P49841 | 2/20 | 0.51 |
| ▸ | BACE1 | P56817 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CASP3 | P42574 | 2/20 | 0.49 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.49 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2747523 | 1.00 | FBP1 (0.62) | FBP1NR1H4MAOBRAB9ANPC1 | |
| SCHEMBL2747521 | 1.00 | FBP1 (0.62) | FBP1NR1H4MAOBRAB9ANPC1 | |
| SCHEMBL11215147 | 0.86 | MAOB (0.55) | FBP1MAOBRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL11215148 | 0.86 | MAOB (0.55) | FBP1MAOBRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2748716 | 0.85 | MAOB (0.63) | FBP1MAOBKDM4EALDH1A1MEN1 | |
| SCHEMBL2748717 | 0.85 | MAOB (0.63) | FBP1MAOBKDM4EALDH1A1MEN1 | |
| SCHEMBL2748715 | 0.85 | MAOB (0.63) | FBP1MAOBKDM4EALDH1A1MEN1 | |
| SCHEMBL11213932 | 0.85 | NR1H4 (0.57) | NR1H4MAOBRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL11213931 | 0.85 | NR1H4 (0.57) | NR1H4MAOBRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL9627326 | 0.85 | MAOB (0.58) | FBP1MAOBRAB9ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178679-B2 | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptors | ALMIRALL, S.A. (ES) | 2012-05-15 | — | — | US | disclosed |
| US-20100324000-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTORS | ALMIRALL, S.A. (ES) | 2010-12-23 | — | — | US | disclosed |
| EP-2212276-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | Almirall, S.A. (ES) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009068177-A1 | DERIVATIVES OF 4-(2-AMINO-1 -HYDROXYETHYL)PHENOL AS AGONISTS OF THE β2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. (ES) | 2009-06-04 | — | — | WO | disclosed |
| US-7511063-B2 | High affinity quinoline-based kinase ligands | SCHERING CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-20080045568-A1 | Novel high affinity quinoline-based kinase ligands | SCHERING CORPORATION | 2008-02-21 | — | — | US | disclosed |
| WO-2007022241-A2 | NOVEL HIGH AFFINITY QUINOLINE-BASED KINASE LIGANDS | SCHERING CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20030171435-A1 | New amphetamine derivatives, antibodies against them and pharmaceutical compositions containing them | DRUG ABUSE SCIENCES, INC. | 2003-09-11 | — | — | US | disclosed |
| WO-2003061595-A2 | ANTIBODIES AGAINST AND COMPOSITIONS CONTAINING NEW AMPHETAMINE DERIVATIVES | DRUGABUSE SCIENCES S.A.S. (FR) | 2003-07-31 | — | — | WO | disclosed |
| EP-1331219-A1 | New amphetamine derivatives, antibodies against them and pharmaceutical compositions containing them | Drug Abuse Sciences, Inc. (US) | 2003-07-30 | — | — | EP | disclosed |
| EP-0023385-B1 | ETHANAMINE DERIVATIVES, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS | BEECHAM GROUP PLC (GB) | 1982-12-15 | — | — | EP | disclosed |
| US-4338333-A | ANTIOBESITY, HYPOGLYCEMIC | BEECHAM GROUP LIMITED (GB) | 1982-07-06 | — | — | US | disclosed |
| EP-0023385-A1 | Ethanamine derivatives, their preparation and use in pharmaceutical compositions | BEECHAM GROUP PLC (GB) | 1981-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324000-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTORS | ADRB2, ADRB1, ADRA2C | FBP1 3388/4885NR1H4 130/4885MAOB 498/4885 |
| US-20080045568-A1 | Novel high affinity quinoline-based kinase ligands | CDKL2, CDK2, CDKL1 | FBP1 2551/4885NR1H4 3166/4885MAOB 2894/4885 |
| US-20030171435-A1 | New amphetamine derivatives, antibodies against them and pharmaceutical compositions containing them | TAAR5, CHAT, CES2 | FBP1 4488/4885NR1H4 228/4885MAOB 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.